Evidence-Practice Gaps in Postdischarge Initiation With Oral Anticoagulants in Patients With Atrial Fibrillation (scientific article published on 04 December 2019)

Oral anticoagulants versus antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no history of stroke or transient ischemic attacks

Q24244298

Clinical and Economic Implications of AF Related Stroke

Q28077788

Dabigatran versus warfarin in patients with atrial fibrillation

Q28256895

Epidemiology of atrial fibrillation: European perspective

Q28315439

Atrial fibrillation as an independent risk factor for stroke: the Framingham Study

Q29614200

Rivaroxaban versus warfarin in nonvalvular atrial fibrillation

Q29614696

The Australian Pharmaceutical Benefits Scheme data collection: a practical guide for researchers

Q31015134

Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation

Q35003773

50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study

Q36005690

Effect of Adherence to Oral Anticoagulants on Risk of Stroke and Major Bleeding Among Patients With Atrial Fibrillation

Q36714127

Early real-world evidence of persistence on oral anticoagulants for stroke prevention in non-valvular atrial fibrillation: a cohort study in UK primary care

Q37312543

Underuse of oral anticoagulants in atrial fibrillation: a systematic review

Q37770666

Primary non-adherence in general practice: a Danish register study

Q38206382

Suboptimal Use of Oral Anticoagulants in Atrial Fibrillation: Has the Introduction of Direct Oral Anticoagulants Improved Prescribing Practices?

Q38728028

Early non-persistence with dabigatran and rivaroxaban in patients with atrial fibrillation

Q38912202

Estimating the current and future prevalence of atrial fibrillation in the Australian adult population.

Q39058682

Aspirin Instead of Oral Anticoagulant Prescription in Atrial Fibrillation Patients at Risk for Stroke

Q39658587

Oral anticoagulants and intracranial hemorrhage. Facts and hypotheses.

Q40458214

Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation

Q42908804

Temporal trends in medication use and outcomes in atrial fibrillation.

Q43988519

Outcomes for people with atrial fibrillation in an Australian national audit of stroke care.

Q45802093

Atrial fibrillation pharmacotherapy after hospital discharge between 1995 and 2004: a shift towards beta-blockers

Q46765460

Patterns of long-term use of non-vitamin K antagonist oral anticoagulants for non-valvular atrial fibrillation: Quebec observational study.

Q48233579

The impact of non-vitamin K antagonist oral anticoagulants (NOACs) on anticoagulation therapy in rural Australia.

Q50103243

Medium- to long-term persistence with non-vitamin-K oral anticoagulants in patients with atrial fibrillation: Australian experience.

Q53345937

Provider Specialty, Anticoagulation Prescription Patterns, and Stroke Risk in Atrial Fibrillation.

Q54982283

Risks and benefits of direct oral anticoagulants versus warfarin in a real world setting: cohort study in primary care.

Q55518927

Stroke prevention in atrial fibrillation

Q56607937

Rapid and substantial increases in anticoagulant use and expenditure in Australia following the introduction of new types of oral anticoagulants

Q60046275

National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand: Australian Clinical Guidelines for the Diagnosis and Management of Atrial Fibrillation 2018

Q90752977

Evaluating utilization patterns of oral anticoagulants in routine care

Q91640443

Management of Patients With Atrial Fibrillation

Q92384979

Persistence with therapy among patients treated with warfarin for atrial fibrillation

Q95445320

P433

issue

P407

language of work or name

English